Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Click to increase image sizeClick to decrease image size

Authorship contributions

CKC and LJN: Designed the study.

CKC, PJ and MN: Collected and assembled the data.

CKC, YQ and LF: Analyzed and interpreted the data.

CKC, MR, FS, NF, YQ, LF, JW, SSN, FBH, CF, LJN: Wrote the manuscript.

All authors gave final approval for the manuscript.

MR, FS, NF, LF, JW, SSN, FBH, CF, LJN: Provided study materials and patients.

Disclosure statement

CKC, MR, YQ, LF, FS, PJ, MN, LF, FBH: No conflicts of interest.

NF: received research support from Celgene, Roche, Janssen, TG Therapeutics and AbbVie; served as consultant and advisory board member for Celgene, Roche, Janssen, TG therapeutics and AbbVie.

JW: has received research support from Novartis, Celgene, Janssen, Kite/Gilead, Unum, Genentech, Curis and 47 Inc; served as consultant and advisory board member for Novartis, Celgene, Juno, Janssen, Kite/Gilead, MorphoSys, Genentech and Curis.

SSN: has received research support from Kite/Gilead, Cellectis, Poseida, Merck, Acerta, Karus, BMS, Unum Therapeutics, Allogene, and Precision Biosciences; served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, Merck, Precision Biosciences, Cell Medica, Incyte, Allogene, Calibr, and Legend Biotech; has patents related to cell therapy.

CF: has received research support from AbbVie, Acerta Pharma, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Millenium/Takeda, National Institutes of Health, Onyx Pharmaceuticals, Pharmacyclics and Spectrum Pharmaceuticals; served as consultant and advisory board member for Spectrum Pharmaceuticals, Celgene, Optum Rx, Seattle Genetics, Kite/Gilead and Bayer.

LN: has received research support from TG Therapeutics, Janssen, Genentech and Celgene; has served as consultant and advisory board member for TG Therapeutics, Novartis, Janssen, Spectrum Pharmaceuticals, Kite/Gilead, Genentech, Bayer and Celgene.

Additional information

Funding

This work was supported in part by the Cancer Center Support Grant (CCSG).